

Company Announcement

5 October 2010

Bavarian Nordic's MVA-BN® patent stands in European validity challenge

Kvistgård, Denmark, October 5, 2010 - Bavarian Nordic A/S (OMX: BAVA) announced today that the company successfully defended its core patent covering the MVA-BN® technology despite aggressive attempts from competitors to revoke the patent in Europe.

The patent was granted in December 2005 and after the nine month opposition period in which any third party can file an opposition against any patent granted in a European jurisdiction, seven companies opposed the patent. The opposition proceeding has been pending at the European Patent Office for several years.

After an oral hearing in the first instance the Opposition Division today rendered its decision to uphold the patent with certain amended claims.

Bavarian Nordic's President & CEO, Anders Hedegaard commented: *"We are very pleased with the decision by the first instance to uphold our core patent, thus confirming its uniqueness. We have substantially invested our resources to develop our MVA-BN® technology and our efforts have led to the creation of valuable intellectual property, which we successfully have defended today."*

Asger Aamund
Chairman of the Board

Contact

Anders Hedegaard, President & CEO. Phone +45 23 20 30 64

About Bavarian Nordic

Bavarian Nordic is a leading industrial biotechnology company developing and producing novel vaccines for the treatment and prevention of life-threatening diseases with a large unmet medical need. The company's clinical pipeline targets cancer and infectious diseases, and includes seven development programmes. Two programmes under preparation for Phase III: PROSTVAC™, a therapeutic vaccine for advanced prostate cancer is being developed under a collaboration agreement with the National Cancer Institute, and IMVAMUNE®, a third-generation smallpox vaccine is being developed under a contract with the US government.

Bavarian Nordic is listed on NASDAQ OMX Copenhagen under the symbol BAVA.

For more information please visit www.bavarian-nordic.com

Forward-looking statements

This announcement includes "forward-looking statements" that involve risks, uncertainties and other factors, many of which are outside of our control that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.